Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (18)
Andere mochten auch
Andere mochten auch (20)
Ăhnlich wie 9th pharmacovigilance 2015
Ăhnlich wie 9th pharmacovigilance 2015 (20)
KĂźrzlich hochgeladen
KĂźrzlich hochgeladen (20)
9th pharmacovigilance 2015
- 1. V. KALAISELVAN, ARUN BHATT, DEEPA ARORA, BHASWAT CHAKRABORTY, BABITA KIRODIAN, NIPOM DEKA, SHASHIDHAR SWAMY, MANISH VERMA, KARTHIK BABU, CHIRAG TRIVEDI, PRIYA CHATTERJEE, MILIND ANTANI, DEEPTI SANGHAVI, SANDEEP SEWLIKAR, ANAND HARUGERI, Indian Pharmacopoeia Commission Ministry of Health and Family Welfare Govt. of India, Principal Scientific Officer ClinInvent Research, Lupin, Cadila, Bristol Myers Squibb, Abbott Wockhardt, Sanofi, Sanofi, Sanofi, Merck Serono, Nishith Desai Associates, Tata Consultancy Services, Johnson and Johnson, President Vice President - Pharmacovigilance & Global Head - Drug Safety & Risk Management Senior Vice President Head of Country Pharmacovigilance Regional Pharmacovigilance Manager, Asia, Africa & Middle East Head Pharmacovigilance Director Medical Affairs Affiliate Pharmacovigilance Head Director & Head of Clinical Study Unit Director - Regulatory Affairs Partner In-Charge - Pharma LifeSciences Patient Safety and Regulatory Affairs Manager Assistant Manager - Medical Writing Manager â Clinical Affairs Astrazeneca, MOHAMMAD SALIM, Pfizer, Country Safety Lead ? ? ? ? ? ? ? ? ? ? ? ? ? Legislation, policies, systems, technology, communication strategies Audits and Inspections Benchmarking drug safety and pharmacovigilance Improving patient care and safety Safety reporting PV for Biologics â new legislation, new requirements Challenges and Opportunities Enhancing quality in healthcare Signal detection Proper balance in relationships: Sponsor â Site â CRO & Patients Developing regulatory framework Be part of a major networking opportunity Network in our combined exhibition and catering area Key Speakers Include Special reasons to Attend Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference. Why Should You Attend Learn, Partner, Innovate, Suceed Book now... Register now to secure your seats Call +91 44 64536444 or email - info@virtueinsight.com âEnsuring safer drugs to market by analyzing latest developments in pv, drug safety and risk managementâ 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India Conference Hashtag - #VI_Pharma 9th Pharmacovigilance 2015 GIRISH PARHATE, RAJASHRI SURVASE OJHA, VANDANA JOLAD, Bayer Pharmaceuticals, Raaj GPRAC, VIaTAL Pharma, Head Regulatory Affairs Founder and MD Director
- 2. ORGANIZED BYORGANIZED BY SUPPORTED BYSUPPORTED BY FOR DELEGATE REGISTRATIONS:- Our potent conference agenda delivering the latest information and the world class leaders as speakers attract delegates to attend from around the world. We aim for our attendees to be equipped with knowledge of latest developments & enable them to network with the industry key personnel. Delegate Registration - delegate@virtueinsight.com FOR SPONSORSHIP OPPORTUNITIES:- Sponsorship or exhibition is the best way to speed network with decision makers. The world leader speakers in our conferences attract niche delegates from all over the world. This would be a wonderful opportunity to reach the right audience and save money and time on all your other advertising gimmicks. To give you an advertising edge we constantly update the industry pioneers via emails/newsletters about the event and advertise the event via different forms of media. Sponsorship Enquires sponsor@virtueinsight.com- 9th Pharmacovigilance 2015 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India GOLD PARTNERGOLD PARTNER EXHIBITOR
- 3. CONFERENCE INTRODUCTION:- After the successful journey of a series of 8 Pharmacovigilance yearly conferences, Virtue Insight is proud to announce its 9th Pharmacovigilance 2014 in India. India is now being recognized as the âGlobal pharmacy of generic drugsâ & has distinction of providing generic quality drugs at affordable cost. India is also emerging rapidly as a hub of global clinical trials & a destination for drug discovery & development. Pharmaceutical sales in India are expected to rise by 14.4 per cent to USD 27 billion in 2016 from last year, but the life sciences and health care industry is up against challenges such as quality management and meeting global standards. Regulatory authorities have inspected pharmaceutical companies for almost 15 years. This has meant that there is now a level of expectation from the regulators and industry that there has been enough time and knowledge to understand what is required as a responsible license holder. Companies need to ensure that all pharmaceutical products are managed properly in terms of the collection, assessment and reporting of adverse reactions such that any serious safety issues can be identified early and acted upon quickly to protect patients from harm. The aim of this conference is that through both a practical review of the purpose of internal audits to assess a companyâs current systems and understand potential pitfalls, there is also a review of the current Regulatory attitudes and mechanisms for Inspections, the level of findings and penalties which are facing pharmaceutical companies â both big and small; innovator and generic. As the regulatory landscape continues to evolve it is crucial that you are keeping abreast of the changes impacting the drug safety industry to ensure that your pharmacovigilance strategies are robust and geared to compliance. In addition to this effective risk management and minimization efforts and comprehensive benefit: risk analysis of drugs must lay the foundations for a strong drug safety strategy. 9th Pharmacovigilance 2015 will discuss the pressing concerns confronted with regard to drug safety, addressing the risks, time line, budget constraints, effectively tackling key challenges, overcoming trial agreement and site contract negotiation hurdles. Top pharmaceutical, biotech, and regulatory representatives will discuss the current complexities and controversies in pharmacovigilance and risk management throughout all phases of development. The conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. Itâs the latest in Virtue Insightâs series of successful pharmacovigilance events. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, this event will provide an important platform for pharmacovigilance stakeholders from India to discuss and share best practices in expediting pharmacovigilance development in India. It gives me great pleasure in welcoming all of you to the Virtue Insightâs 9th Pharmacovigilance 2015. I wish and pray that all our efforts will be beneficial to our industries and to our country at large. KEY THEMES DISCUSSED AT THIS CONFERENCE:- ⢠Update yourself with respect to terms of legislation, policies, systems, technology, communication strategies and best practice in PV ⢠Developing Pharmacovigilance into high quality management system and its components ⢠Audit and Inspection: Realistic steps for a fruitful consequence ⢠Benchmarking drug safety and pharmacovigilance ⢠Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions ⢠How to use the data sources and observational research for effective safety analysis ⢠Training for drug safety - reporting duties, audits and expectations â risk based inspections ⢠Safety reporting in licensing agreement ⢠PV for Biologics â new legislation, new requirements ⢠Challenges and Opportunities in PV lifecycle management ⢠Good supply chain management practices for medicine distribution ⢠Accelerating new medicine introduction in developing world & overcoming challenges ⢠Developments in Pharmacovigilance, drug safety & risk management to ensure safer drug ⢠Determining the steps and strategies for enhancing quality in healthcare ⢠Emerging signal detection data gathering successful tools to highlight emerging risks ⢠Maintaining proper balance in relationships: Sponsor â Site â CRO & Patients ⢠The developing regulatory framework in advanced and developing markets ⢠Accelerating new medicine introduction in developing world & overcoming challenges ⢠Be part of a major networking opportunity WHO WILL YOU MEET:- Vice Presidents, Directors, CROâs, Heads and Managers of: Pharmacovigilance Strategy, Drug Safety/Risk Management, Information and Clinical Data Management, Clinical Research, Research & Development, Product Safety/Assurance Assessment, Patient Safety & Outcomes Research & Data Analysis, Epidemiology project management, Regulatory Affairs and Compliance, Sales & Marketing, Biotech manufacturers Pharmaceutical organizations, Generic pharmaceutical companies, Contract research organizations, Patient recruitment companies, Government- Department of health, Non-profit organizations/ Association, Consultants From the following: 9th Pharmacovigilance 2015 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India WHY SHOULD YOU ATTEND? Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
- 4. 08:30 â Coffee and registration - An opportunity to meet and to network with your conference colleagues 09:30 â Morning Chair's opening remarks 09:40 â Morning Keynote Address 1: Indian Regulations and Patient Safety during Clinical Trials ClinInvent Research 10:10 â Lessons to learn from management of safety data from patient support and market research programs 10:40 â Morning Coffee/Tea & Discussion ⢠Patient safety perspective during clinical trials ⢠Indian Regulatory spectrum for protecting patient safety ⢠Global regulatory scenario for patient safety ⢠Recommendations for Indian regulatory system for patient protection clinical trials President, ⢠Overview of legal requirements ⢠Perspectives in handling of safety information ⢠Collaborations with service provider ⢠Revealing the true value of patient recruitment ⢠The evolution and implementation of patient-centered trials ⢠Improve Protocol Feasibility, Trial conduct and operations by learning from a key partner in research ⢠Evolution of physician and patient retention in post-marketing and real-world research â Use of Prediction and prevention methods to optimize participation ⢠How pharmacists can be pivotal in helping patients ARUN BHATT, 11:00 â Keynote Panel Discussion: Challenges and Opportunities in PV lifecycle management ⢠Staying ahead in the race - Updates on PV - Current trends for PV, and new and future guidelines ⢠Exploring the current and future drug safety landscape ⢠What can we learn from successful experiences from RoW? ⢠Identifying the key opportunities for biopharmaceutical outsourcing in the area of PV ⢠Litigation, risk and latest developments and trends within PV technology ⢠Open innovation/cross-Industry collaboration and the current state of affairs in pharma ⢠How to create a proactive drug safety culture? 11:40 â Adverse event monitoring in clinical trials and post- marketing surveillance 12:10 - Effective Pharmacovigilance: from Information to Clinical Practice , Lupin ⢠Core and emerging challenges to monitoring adverse drug events ⢠Types of ADR, Methods of ADR Monitoring including ICSR ⢠Formulating improvements and establishing key performance indicators for continual quality assessment ⢠Timely and effective benefit-risk communication to patients and physicians ⢠Combining adverse event monitoring throughout clinical trials and post-marketing surveillance ⢠Establishing key performance indicators for making timely safety reports and continuous quality improvements ⢠Challenges of running and reporting ADRs in India ⢠Total PV includes Identification, Characterization, Management and Prevention of ADRs ⢠Industry Focus from compliance perspective is mainly on identification of new ADRs ⢠Optimum utilization of this knowledge is desirable to prevent ADRs or minimize the associated morbidity & mortality ⢠All stakeholder should be involved in communication Vice President- Pharmacovigilance & Global Head- Drug Safety & Risk Management, DEEPA ARORA MARKET OVERVIEW & ANALYSIS CHALLENGES & OPPORTUNITIES 9th Pharmacovigilance 2015 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India ⢠Dissecting the challenges in vaccine safety surveillance ⢠Evaluating the various aspects of pharmacovigilance in conducting trials. Founder and MD, Head Pharmacovigilance, Affiliate Pharmacovigilance Head, Manager â Clinical Affairs, Regional Pharmacovigilance Manager, Asia, Africa & Middle East, Patient Safety and Regulatory Affairs Manager, Moderator: Raaj GPRAC Panellists: Wockhardt Sanofi Johnson and Johnson Abbott Astrazeneca RAJASHRI SURVASE OJHA, SHASHIDHAR SWAMY, KARTHIK BABU, SANDEEP SEWLIKAR, NIPOM DEKA, ANAND HARUGERI,
- 5. 12:40 â Networking luncheon 14:00 â PV for Biologics â new legislation, new requirements 14:30 - Pharmacovigilance programme of India (PvPI): achievements and challenges Indian Pharmacopoeia Commission Ministry of Health and Family Welfare Govt. of India 15:00 â Afternoon Tea/Coffee ⢠High level overview of why biologics and their specific characteristics which give rise to unique challenges for PV ⢠Importance of accurate track and trace ⢠Requirements of the PV legislation and what it means for Stakeholders ⢠Indian Pharmacopoeia Commission (national coordinating centre for PvPI) role ⢠ADRs reporting: India experiences ⢠Current status: national and international level ⢠Channels of ADRs reporting ⢠Recommendations to CDSCO Principal Scientific Officer,V. KALAISELVAN, 17:00 Chairpersonâs closing remarks and end of conferenceâ 17:10 - 18:00 - Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting QUALITY â SAFETY â SIGNAL DETECTION REGULATORY 9th Pharmacovigilance 2015 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India 15:20 Panel Discussion The necessary shift of Sponsors and CROs from adversaries to partners â â ⢠In what way can the realistic expectations, clear communications, shared understandings, practical policies, and efficient problem resolution methods be developed between sponsors, sites & CROs ⢠Patient-centric approach to clinical trials ⢠How will CRO's analyse the current opportunities to invest in early stages of drug discovery or biotechnology start-ups? ⢠The current perspectives on the future of outsourcing in Asia ⢠Advantages of a collaborative clinical trial alliance for greater efficiency and cost reduction ⢠Best practices for aligning critical performance and operational data between sponsor/CRO ⢠An overview of realized performance gains through partnership ⢠The performance impact of a shared decision making platform ⢠Integrating clinical trial supply by streamlining the trial set up and managing drug inventory for successful partnerships SPONSOR â SITE â CRO - PATIENTS 16:00 Panel Discussion The developing regulatory framework in advanced and developing markets Moderator: Nishith Desai Associates Panellists: Bayer Pharmaceuticals Bristol Myers Squibb VIaTAL Pharma Merck Serono Sanofi â â ⢠Keep abreast with the changing regulations of PV ⢠Determining where future challenges could arise ⢠A brief recap of recent regulatory developments. Ensuring you comply with market requirements ⢠Current PV practices ⢠PRAC: â regulatory & industry perspective ⢠Regulatory considerations towards staffing and recruitments Partner In-Charge - Pharma LifeSciences, Head Regulatory Affairs, Head of Country Pharmacovigilance, Director, Director - Regulatory Affairs, Director Medical Affairs, MILIND ANTANI, GIRISH PARHATE, BABITA KIRODIAN, VANDANA JOLAD, PRIYA CHATTERJEE, MANISH VERMA, Moderator: VIaTAL Pharma Panellists: Tata Consultancy Services Cadila Sanofi Pfizer Director, Assistant Manager - Medical Writing, Senior Vice President, Director & Head of Clinical Study Unit, Country Safety Lead, VANDANA JOLAD, DEEPTI SANGHAVI, BHASWAT CHAKRABORTY, CHIRAG TRIVEDI, MOHAMMAD SALIM,
- 6. FLOOR PLAN:- Book your stalls now before they run out !!! 1 2 5 3 4 CONFERENCEHALL1 CONFERENCEHALL2 CONFERENCEHALL3 1 Coffee / Tea / Networking Area POOL SIDE AREA NETWORKING LUNCHEON 4 5 6 2 3 REGISTRATION DESK 6 9th Pharmacovigilance 2015 FLOOR PLAN - Book your stalls now before they run out !!! 7 7
- 7. Aark Store Abbott Abbott India Abbvie Accenture Services Accutest Research Laboratories Actelion Pharmacetuicals Acton Biotech Acunova ADAMAS Consulting Adcock Ingram Healthcare Aegerion Pharmaceuticals Afra Pharma Consultant Agency for Medical Products & Medical Device of The Republic of Slovenia Agilent Technologies Ajanta Pharma Ajaxdotcom Alembic Pharmaceuticals Alkem Labs AMCo Amgen Amgen Technology Apollo Hospitals Aprova Aptiv Solutions Archimed Medical Communication Aris Global Arklus CTSS Astellas Pharma Astrazeneca Auden Mckenzie (Pharma Division) Aurobindo AXESS Azin Pharma Bagdad medical college, Barrington James Baxter Healthcare Bayer Bayer Pharma AG Bayer Pharmaceuticals Bharat Serums & Vaccines Biocon BioLinx India Biological E BioSpectrum India Biosphere Clinical Research BJ Medical college Bluefish Pharmaceuticals Bodhi Global Boehringer Ingelheim Bookmytraining.com Boots Pharmaceuticals Bristol Myers Squibb Bristows Business Vibes Business Wire Cadila Pharmaceuticals Cambridge Regulatory Services Catalyst Clinical Services Celgene Europe Celon Laboratories Center for Cellular & Molecular Biology Centre for Clinical Research and Training Chiltern International Cipla Ciron Drugs & Pharmaceuticals CISCO SYSTEMS CKA Group Clearight Infotech Clinical Research & Healthcare Clinical Research Learning and Dev Cliniminds Clininvent Researc Cognizant Cognizant Technology Solutions Consultant Psychologist & Freelance Journalist CSD MR UK CSIR Partial list of attendees from our previous Pharmacovigiliance:- DNA India Dr Lal Path Labs Dr. Ebeling & Assoc Dr. Reddy's Laboratories Drug Safety Research Unit (DSRU) Drug Safety Solutions DSRU Ecron Acunova EGA (European Generic Medicines Association) Ege University Egis Pharmaceuticals Eisai Pharmaceuticals ELC Research Elder Pharmaceuticals Eli Lilly & Company Emcure Pharmaceuticals Ennovent Espire Health Research EUDRAC European Regulatory Solutions Express Pharma EXTEDO Famy Care FDC Flamingo Pharmaceuticals Foresight group Forte Research Fresenius Kabi Oncology Fulford GCP QA Auditing and Consulting Inc Generic Licensing Genpact German Pharmaceutical Industry Association Gilead Sciences International GlaxoSmithKline Pharmaceuticals Glenmark Global PharmaTek Going to Meet Good Compliance Services Gufic Biosciences HCL Technologies - BPO Services Healthcare Data Hetero Labs Hikma Pharmaceuticals Hydrogen Group i3 Research ICPC.biz ICRI IIHMR, Jaipur. IMS Health Indian Immunologicals Innovaro Intas Pharmaceuticals Inventia Healthcare Inventiv Health Clinical IPCA Laboratories IPPro Lifesciences ITS-DCHRC Janssen Infectious Diseases JASIC Asia Bio Network JB Chemicals & Pharmaceuticals JensonR+ Limited Johnson & Johnson CSL Behring Cytel Statistical Software & Services Dabur Indiah Daiichi Sankyo Development DBMS Consulting Deloitte Consulting K.J Somaiya Medical College Karmic Lifesciences KEM Hospital Keyrus Biopharma Kinapse KJ Somaiya Medical college KPMG Kusum Healthcare Kuwait National Petrolium Company Kuwait University, Faculty of Pharmacy L.T. Medical College Lambda Therapeutic Research Launtech Teaching Hospital LG Life Sciences Lotus Labs Lupin Macleods Pharmaceuticals Macro Care Maharashtra University of Health Sciences Manipal AcuNova Markets&Markets Medac UK Medanta-The Medicity Medical Newstoday Medicounts Life Sciences Medlmmune MedZine Mega Lifesciences Megawecare Merck Serono Merck Sharp & Dohme MHRA Micro Therapeutic Research labs MMS MSD India Mundipharma Research Mylan Laboratories Nanokinetik Navitas Life Sciences NDA Nelsons Netherlands Foreign Investment Agency Nicovations Niko Infra Licensing Nishith Desai Associates Norweigen Medicines Agency Norwich Clinical Services Novartis Novartis Consumer Health Novartis Pharma S.A.S. Novo Nordisk Oracle Corporation Oracle Life Sciences Orion Pharma Orphan Europe Otsuka Europe Dev & Commericalisation Oviya Medsafe OXON Epidemiology Panacea Biotec PAREXEL International PCS Pharmacovigilance LTD PDP Couriers Pfizer Pharma & Healthcare Insights Pharma Asia Pharma Focus Asia Pharma Mirror Pharmacosmos pharmaphorum PharmaVOICE Pharmcast Pierre Fabre Medicament Piramal Healthcare Piramal Life Sciences Plethico Pharmaceuticals PPCE Pvt. Ltd PPD PRA Health Sciences Prism Ideas ProductLife Provenance research Public Health Foundation of India PVCON Pharmacovigilance Consulting Services Quintiles Raaj GPRAC Ranbaxy Laboratories Ranbaxy Research Laboratory Rasayani Biologics Real Staffing RegPak BioPharma Consulting Reliance Life Sciences Results Healthcare Rite-Aid Pharmacy Roche Pharmaceuticals Roche Products Saffron Media Sandoz Sanofi Sanofi Aventis Sanofi-Aventis (Suisse) SA Sciformix Technologies Shantha Biotechnics Shasun Pharmaceuticals Shionogi Sidley Austin SIRO Clinpharm Sitec Labs Pvt Ltd SLARC Springer Sri. Devaraj URS Medical College SRL ST. JAMESâS PLACE Stallergenes Stempeutics Research Sticares Interact Strides Arcolab Sun Pharmaceutical Industries Swami Samarth Pharmatech Symbiorph Clinical Trialogy Symogen Synchron Research Services Synowledge TAKE Solutions Takeda Oncology: Millennium Pharma Takeda Pharmaceuticals TauRx Therapeutics TCS Tech Observer Techsol Corporation Techsol Systems Teofarma S.R.L The Medicines Company Thinki TN Medical College&BYL Nair Hospital Torrent Pharmaceuticals Torrent Research Center Transcrip Partners LLP UBC UCB Celltech UCB India Unichem Laboratories United BioSource Corporation University of Hertfordshire Until ROI USV Veeda Clinical Research Vetmedico bvba VIaTAL Pharma Consulting Vigi Medsafe VIVAN Life Sciences Voisin Consulting Life Sciences Watson Pharma Weifa AS Wipro Wipro BPO Witness Witness Magazine Wockhardt World Customs Organization World Pharma Today Xylem Clinical research Yes Regulatory Healthcare Services YourStory.in Zigzag Associates Zydus Cadila
- 8. For Multiple Bookings Special Price INR Registration Form Details: Methods of Payments: Photocopy this form... 1 Day conference Fee: INR 07,000 + Tax Forename ............................Surname ................................ Job Title ..............................Company ................................ Official Contact Number ....................................................... Address ............................................................................. ............................................................................. Country ...............................Postcode.................................. Phone ..................................Fax ........................................ Email ................................................................................. I confirm that I have read & agree to the terms and conditions of booking..... (Please Tick) Signature ........................................................................... Complete and return the above registration form via post or email, together with your cheque payable to Virtue Insight. Account Name - Virtue Insight Bank Address - Indian Bank. 118 - 119, Indira Nagar, Valasaravakkam, Chennai 600 087,Tiruvallur district,Tamil Nadu, India (Please Tick) By Cheque - By Bank Transfer - Account Number - 830092431 Queries: General information Venue: Payment terms: Substitutions/name changes or cancellations: Indemnity: Fee: How we will contact you: Should you have any questions on bookings, Please feel free to contact us. Email: Web: India Office: Tel: +0091 44 2377 0517 Virtue Insight requires the full amount to be paid before the conference. Virtue Insight may refuse entry to delegates who have not paid their invoice in full. There is a 50% liability on all bookings once made, whether by post, fax, or email. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences and executive briefings. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and substitutions must be from the same company or organization and are not transferable between countries. Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we will refund your registration fee and we will try to reschedule the event. The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel or hotel accommodation. Virtue Insight's preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you. info@virtueinsight.com http://www.virtueinsight.com www.virtueinsight.com RESERVATION PRICING: www.virtueinsight.com Early Bird Discount Rate Till 20th July 2015 Standard Rate (From 21st July 2015) Group Discounts Group Discounts Spot Registration:- Methods of Payments: By Bank Transfer: 1 Day conference - per delegate - Fee: INR 06,000 + Tax 1 or 2 delegates - per delegate - Fee: INR 07,000 + Tax For 3 or 4 delegates - per delegate - Fee: INR 06,500 + Tax For 5 and above delegates - per delegate - Fee: INR 05,000 + Tax 1 Day conference per delegate - Fee: INR 08,000 + Tax Forename ............................Surname ................................ Job Title ..............................Company ................................ Official Contact Number ....................................................... Address ............................................................................. ............................................................................. Country ...............................Postcode.................................. Phone ..................................Fax ........................................ Email ................................................................................. I confirm that I have read & agree to the terms and conditions of booking..... (Please Tick) Signature ........................................................................... By Cheque - Complete and return the above registration form via post or email, together with your cheque payable to Virtue Insight. Account Name - Virtue Insight Account Number - 830092431 Sort code - IDIB000V080 Bank Address - Indian Bank. 118 - 119, Indira Nagar, Valasaravakkam, Chennai 600 087,Tiruvallur district,Tamil Nadu, India Registration Form Details: REGISTRATION FORM Queries: General information Venue: Payment terms: Substitutions/name changes or cancellations: Indemnity: Fee: How we will contact you: Should you have any questions on bookings, Please feel free to contact us. Email: Web: India Office: Tel: +91 44 64536444 Kohinoor Continental Hotel Andheri Kurla Road Andheri ( E ) Mumbai 400059 - India Tel: 91 22 66919000 / 91 22 28209999 Virtue Insight requires the full amount to be paid before the conference. Virtue Insight may refuse entry to delegates who have not paid their invoice in full. There is a 50% liability on all bookings once made, whether by post, fax, or email. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places between conferences and executive briefings. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and substitutions must be from the same company or organization and are not transferable between countries. Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we will refund your registration fee and we will try to reschedule the event. The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel or hotel accommodation. Virtue Insight's preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you. info@virtueinsight.com http://www.virtueinsight.com News Updates: Please tick if you do not wish to receive email updates in the future